A Phase I Study of MEDI9447 (Oleclumab) in Japanese Participants

Study identifier:D6070C00006

ClinicalTrials.gov identifier:NCT03736473

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of MEDI9447 (Oleclumab) in Japanese Patients with Advanced Solid Malignancies

Medical condition

Advanced solid malignancies

Phase

Phase 1

Healthy volunteers

No

Study drug

MEDI9447

Sex

All

Actual Enrollment

6

Study type

Interventional

Age

20 Years - 130 Years

Date

Study Start Date: 07 Nov 2018
Primary Completion Date: 19 Jun 2019
Study Completion Date: 19 Jun 2019

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Nov 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria